Trending Stock News

Ascendis Pharma A/S (ASND) At $66.29 Forms Top; 4 Analysts Are Bullish SKYEPHARMA PLC ORD 100P (LON:SKP) Last Week

Ascendis Pharma A/S (ASND) formed multiple top with $68.28 target or 3.00% above today’s $66.29 share price. Ascendis Pharma A/S (ASND) has $2.75B valuation. The stock decreased 0.94% or $0.63 during the last trading session, reaching $66.29. About 66,015 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 130.09% since May 19, 2017 and is uptrending. It has outperformed by 118.54% the S&P500.

Among 4 analysts covering SkyePharma PLC (LON:SKP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SkyePharma PLC had 22 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of SKYEPHARMA PLC ORD 100P (LON:SKP) has “Corporate” rating given on Wednesday, December 16 by N+1 Singer. As per Thursday, July 30, the company rating was maintained by N+1 Singer. N+1 Singer maintained SKYEPHARMA PLC ORD 100P (LON:SKP) on Wednesday, December 23 with “Corporate” rating. The stock has “Corporate” rating by N+1 Singer on Monday, January 11. The stock of SKYEPHARMA PLC ORD 100P (LON:SKP) earned “Corporate” rating by N+1 Singer on Thursday, November 26. The company was maintained on Wednesday, August 26 by Stifel Nicolaus. N+1 Singer maintained the shares of SKP in report on Friday, January 8 with “Corporate” rating. The firm has “Corporate” rating by N+1 Singer given on Wednesday, August 26. The company was maintained on Thursday, January 28 by Stifel Nicolaus. The rating was maintained by FinnCap on Friday, January 22 with “Buy”. See SKYEPHARMA PLC ORD 100P (LON:SKP) latest ratings:

Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma had 24 analyst reports since September 26, 2016 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, September 26 by Wedbush. On Friday, September 1 the stock rating was maintained by Leerink Swann with “Hold”. Wedbush maintained the shares of ASND in report on Friday, January 5 with “Buy” rating. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) on Friday, March 24 with “Outperform” rating. The rating was maintained by Wedbush with “Buy” on Monday, March 19. On Friday, September 22 the stock rating was maintained by Wedbush with “Buy”. On Tuesday, May 15 the stock rating was maintained by Wedbush with “Buy”. Wedbush maintained the stock with “Buy” rating in Monday, February 26 report. The firm earned “Outperform” rating on Tuesday, March 20 by Credit Suisse. The company was maintained on Friday, November 17 by Bank of America.

Analysts await Ascendis Pharma A/S (NASDAQ:ASND) to report earnings on May, 22. They expect $-0.93 EPS, down 12.05% or $0.10 from last year’s $-0.83 per share. After $-1.08 actual EPS reported by Ascendis Pharma A/S for the previous quarter, Wall Street now forecasts -13.89% EPS growth.

It closed at GBX 444 lastly. It is up 0.00% since May 19, 2017 and is . It has underperformed by 11.55% the S&P500.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *